Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > India Revokes Patent for Pfizer’s Sutent

FDAnews Drug Daily Bulletin

Oct. 5, 2012 | Vol. 9 No. 196

India Revokes Patent for Pfizer’s Sutent

India has revoked Pfizer’s local patent for its cancer drug Sutent after hearing a post-grant opposition filed by generic-drug maker Cipla.
Live Mint

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Pharma Blog Watch New Report Examines Efforts to Reduce the Impact of Generic Competition for Lipitor Royal Endorsement for UAE’s Newest Drugmaker Pathway Genomics to Offer BRCA Test

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.